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1. Introduction 
Transmitter release at central synapses and, hence, the strength of synaptic transmission is controlled on a moment-
to-moment basis by activation of auto or heteroreceptors on presynaptic nerve terminals. At glutamate synapses, 
presynaptic NMDA receptors (preNMDArs) exert a tonic facilitatory effect on glutamate release and, thus, mediate 
an instantaneous form of synaptic plasticity. We first demonstrated this functional facilitatory effect at synapses in 
the rat medial entorhinal cortex (EC; Berretta and Jones, 1996a) and subsequently showed that it was mediated via 
Ca2+-entry via the receptor ionophore (probably di-heteromeric GluN1-GluN2B receptors) and could also contribute 
to activity-dependent facilitation (Woodhall et al., 2001 and Chamberlain et al., 2008). It is now apparent that 
preNMDArs are expressed at many sites throughout the CNS, and a widespread role of the receptors in control of 
transmitter release is likely (see Duguid and Smart, 2009). In particular, attention has increasingly focussed on a role 
in long-term synaptic plasticity of excitatory transmission (Humeau et al., 2003, Sjostrom et al., 2003, Samson and 
Pare, 2005, Corlew et al., 2007, Yang et al., 2008, Rodríguez-Moreno et al., 2010 and Larsen et al., 2011). Our 
observation that preNMDAr are highly mobile in the presynaptic terminal membrane in the EC (Yang et al., 2008) 
could indicate an important role in metaplasticity as well. Enhanced expression or sensitivity of the preNMDAr may 
be involved in pathological plasticity associated with epilepsy (Steffens et al., 2005 and Yang et al., 2006). 
NMDAr are modulated by a number of intrinsic regulatory mechanisms. In addition to partial relief from voltage-
dependent Mg2+-blockade, NMDAr activation requires binding of two agonists; the glutamate binding site is located 
on the GluN2 subunit and a co-agonist binding site resides on GluN1 subunits. Both glycine and D-serine are 
available as physiological ligands for the co-agonist site. Although glycine has generally been considered to be the 
endogenous co-agonist, recent studies have indicated that D-serine is more likely to be the activator of the binding 
site at the postsynaptic NMDAr (postNMDAr), and that glycine is maintained at concentrations well below its affinity 
for the binding site by high-affinity transporters in the synaptic cleft (Fossat et al., 2012 and Papouin et al., 2012). 
The source of the endogenous synaptic D-serine may well be adjacent astrocytes (Henneberger et al., 2010 and 
Fossat et al., 2012), although a neuronal origin has not been ruled out (e.g. Wolosker et al., 1999, Kartvelishvily et al., 
2006 and Rosenberg et al., 2010). 
The EC plays a crucial role in declarative and spatial memory storage (e.g. Eichenbaum, 2001, Squire et al., 2004 and 
Witter and Moser, 2006) and in limbic seizure generation and propagation in temporal lobe epilepsy (see Jones and 
Woodhall, 2005). To help understand the role of the preNMDAr in synaptic function in the EC we have investigated 
whether they are subject to regulation by endogenous glycine or D-serine, and whether this regulation may be 
necessary for tonic facilitation of spontaneous glutamate release. Li and Han (2007) previously showed that an 
antagonist at the NMDAr co-agonist site was able to reduce the spontaneous release of glutamate in visual cortex, 
an effect that was reversed by addition of glycine suggesting that endogenous activation of the co-agonist-binding 
site regulated tonic activation of preNMDArs in this area. In the present study we show that preNMDArs in the EC 
undergo a similar endogenous modification, that the endogenous agonist responsible for this is D-serine not glycine, 
and that the source of the D-serine is likely to be astroglial cells. 
2. Materials and methods 
2.1. Ethics statement 
All experiments were performed in accordance with the U.K. Animals (Scientific Procedures) Act 1986, European 
Communities Council Directive 1986 (86/609/EEC) and the University of Bath ethical review document, which 
requires that the number of animals used is kept to a minimum, and every precaution was taken to reduce suffering 
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and stress. At this institution, all research work involving use of animal tissue requires submission of a consideration 
of ethical implications by the principal investigator. This is reviewed by a second investigator, external to the 
research group, and by the Head of Department, and requires signatory approval from both before being reviewed 
by a Departmental Research Ethics Officer (DREO). The DREO discusses any issues raised with the investigator and 
submits a report to the University Ethics Committee detailing the ethical implications of all research within the 
Department. This ensures that the ethical implications of the research have been considered and that there is a 
process in place for managing any ethical issues. 
2.2. Slice preparation 
Brain slices were prepared (Jones and Heinemann, 1988) from juvenile Wistar rats (50–100 g; P28–38). They were 
decapitated following cervical dislocation and the brain removed and submerged in oxygenated artificial 
cerebrospinal fluid (aCSF; see below for composition) at 4 °C. Combined EC-hippocampal brain slices (350 μm thick) 
were cut at 4 °C using a Campden Vibroslice and subsequently stored in oxygenated aCSF at room temperature. 
Slices were left to recover for 1 h before being used for electrophysiological recording. The aCSF contained (in mM) 
NaCl (126), KCl (4), MgSO4 (1.25), NaH2PO4 (1.4), NaHCO3 (24), CaCl2 (2), d-glucose (10), ascorbic acid (0.57), sodium 
pyruvate (5) and creatinine monohydrate (5). To increase neuronal survival and viability, ketamine (4 μM), 
indomethacin (45 μM), aminoguanidine (25 μM), and Coomassie Brilliant Blue (250 nM) were included in the cutting 
solution, and the antioxidants, n-acetyl-l-cysteine (2 μM) and uric acid (100 μM), added to both cutting and storage 
solutions. We have established that the use of the additives facilitates production robust and viable slices, but does 
not affect the pharmacology of glutamate transmission. 
2.3. Whole-cell patch clamp recordings 
After a period of recovery at room temperature, slices were transferred to a chamber on an Olympus BX50WI 
microscope perfused (2 ml/min) with oxygenated aCSF at 31–32 °C, where they were allowed to equilibrate before 
recording commenced. Individual neurones were visualized using DIC optics and an infrared video camera. 
Whole cell patch clamp recordings were made with an Axopatch 200A amplifier using pipettes pulled from 
borosilicate glass on a Flaming-Brown microelectrode puller. AMPA receptor mediated spontaneous excitatory post 
synaptic currents (sEPSCs) were recorded using a Cs-gluconate based solution intracellular solution containing (in 
mM) d-gluconate (100), HEPES (40), QX-314 (1), EGTA (0.6), NaCl (2), Mg-gluconate (5), TEA-Cl (5), phosphocreatine 
(10), ATP-Na (4), GTP-Na (0.3) and MK801 (5 mM). The solution was adjusted to 275–290 mOsm by dilution and pH 
7.3 with CsOH. MK-801 was included in the patch pipettes to allow us to record AMPA-receptor mediated responses 
in isolation and to monitor activity at preNMDArs uncontaminated by postsynaptic receptor effects. We developed 
and validated this approach (Berretta and Jones, 1996b, Woodhall et al., 2001, Yang et al., 2006 and Yang et al., 
2008), and others have used it successfully to block postNMDArs in recorded neurones (Sjostrom et al., 2003, 
Samson and Pare, 2005, Bender et al., 2006, Jourdain et al., 2007, Li and Han, 2007 and Brasier and Feldman, 2008). 
EPSCs were recorded at a holding potential of −60 mV. Signals were filtered at 2 kHz, digitised at 50 kHz, and stored 
using AxoScope software. Series resistance compensation was not employed, but access resistance was monitored at 
5-min intervals throughout recording and cells where it varied by greater than 15% were excluded from analysis. 
Input resistances for the neurones recorded in these studies were of the order 500–570 MΩ. Data recording 
commenced 10–15 min after gaining whole cell access and then continued for at least 15 min during control and 
each drug treatment condition. Miniature EPSCs (mEPSCs) were isolated using tetrodotoxin (TTX; 1 μM). EPSCs were 
analysed offline over a stable 5-min period of recording where spontaneous events were detected using a threshold-
crossing algorithm with Minianalysis software (Synaptosoft, Decatur). 
The average frequency, calculated across a 5-min epoch, was compared before and after drug application. To 
compare amplitudes of spontaneous currents we determined median values for each neurone in the same 5-min 
period as these better reflect the population distributions (normal distribution with a slight skew towards larger 
amplitude events) than arithmetical means. Median values were then averaged in the neuronal populations for 
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comparative illustrative purposes. We have used this approach in a previous study to characterize IPSCs in the same 
neuronal population (Woodhall et al., 2005). Event kinetics were compared via arithmetical means. Statistical 
comparison of drug effects on mean frequency and kinetics and mean median amplitudes within cells employed a 
two-tailed paired t-test. In experiments involving matched slices with and without prior enzyme treatment, 
comparison between neurones was assessed using a two-way ANOVA. In some experiments involving pooled data, 
we additionally compared cumulative probability distributions of interevent intervals using a Kolmogorov–Smirnov 
test. 
2.4. Enzymatic depletion of endogenous D-serine and glycine 
To determine whether glycine or D-serine is the endogenous activator of the co-agonist site we depleted one or 
other of the amino acids from the slices by preincubation with selective enzyme scavengers. An yeast d-amino acid 
oxidase (DAAO), was used to degrade D-serine, whereas a bacterial glycine oxidase (GO) was used to target glycine. 
Recombinant Rhodotorula gracilis DAAO (RgDAAO) and Bacillus subtilis glycine oxidase GO (BsGO) were 
overexpressed in Escherichia coli cells and then purified as described previously ( Fantinato et al., 2001 and Job et al., 
2002). In experiments where they were employed, slices were incubated with enzymes at room temperature in the 
recording chamber for at least 45 min prior to recording, and then continuously during the recording period at 32 °C. 
Matched slices in normal buffer were treated in the same way and alternated with the enzyme treated slices. For 
each experiment a single neurone was recorded from an enzyme treated slice, and a second recording was made in 
an untreated slice from the same animal on that day, so that neurones were matched in that animal. The order of 
recording (treated or untreated) was varied from animal to animal. 
2.5. Source of D-serine in EC 
Previous studies have suggested that a principal source of D-serine in slices is via release from astroglial cells 
(Kartvelishvily et al., 2006, Miya et al., 2008 and Rosenberg et al., 2010). The metabolic status of astroglial cells is 
compromised by sodium fluoroacetate (NFAc). Accordingly, we have determined the effect of NFAc on spontaneous 
release of glutamate in EC. In experiments where this was tested, slices were incubated with NFAc in the recording 
chamber for at least 35 min prior to recording, and also continuously during the recording period. Matched slices in 
normal buffer were treated in the same way and alternated with the NFAc treated slices. 
2.6. Materials 
Salts used in preparation of aCSF were purchased from Merck/BDH or Fisher Scientific (UK). Indomethacin, 
aminoguanidine, n-acetyl-l-cysteine, uric acid, Coomassie Brilliant Blue, NFAc and agents used in the preparation of 
the patch pipette solution, apart from QX-314 (Tocris, UK), were purchased from Sigma (UK). Ketamine was supplied 
by Fort Dodge Animal Health Ltd (Southampton, UK). Drugs were generally stored as frozen, concentrated stock 
solutions in distilled water and applied by dilution in the aCSF perfusion immediately before use. The following drugs 
were supplied by Tocris UK or Ascent Scientific UK: 2-AP5 (D-2-amino-5-phosphonopentanoic acid), DCKA (5,7-
dichlorokynurenic acid), CPPG ((RS)-α-Cyclopropyl-4-phosphonophenylglycine), MCPG ((RS)-α-Methyl-4-
carboxyphenyl-glycine), MK801, glycine, suramin hexasodium salt, CGS15943, D-serine and TTX. UBP 141 was a kind 
gift from Professor David Jane, University of Bristol. 
3. Results 
The experiments were performed on neurones in layer V of the medial EC. Although not specifically identified by dye 
injection, all the selected neurones had identifiable pyramidal cell morphology when viewed with DIC. We stress that 
all recordings were of AMPA-receptor mediated s/mEPSCs with postNMDArs blocked in the recorded neurone by 
intracellular dialysis with MK801. 
3.1. Effects of D-serine and glycine 
The effects of exogenously applied glycine (100 μM) were tested on 4 neurones and the effects are summarised in 
Fig. 1A. The mean frequency of mEPSCs in these neurones was 0.75 ± 0.13 Hz in control conditions. This was similar 
(0.73 ± 0.12 Hz; −4%) in the presence of glycine (Fig. 1A) and there was no significant difference when assessed with 
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a paired t-test. We also compared cumulative probability distributions of interevent interval, and KS analysis showed 
no significant shift in distribution in the presence of glycine reflecting the lack of change in frequency. mEPSCs had a 
mean median amplitude of 6.4 ± 0.2 pA in control and this was not significantly altered during perfusion with glycine 
(6.0 ± 0.2 pA). Additionally, neither sEPSC rise (4.7 ± 0.8 ms v 5.3 ± 0.3 ms) nor decay time (6.3 ± 1.2 ms v 6.3 ± 0.3 
ms) changed during perfusion with the amino acid. 
 
Fig. 1. Effect of D-serine and glycine on sEPSCs in EC neurones. A. The traces show averaged mEPScs in the presence and absence of glycine in a 
single layer V neurone in the EC. The addition of glycine had little effect on the excitatory events. Pooled data from 4 neurones in the bar 
graphs show that neither mean frequency nor amplitude nor was significantly altered. B. Studies with D-serine produced very similar results. A 
slight increase in mean frequency was not significant. 
Similar studies were performed with D-serine (100 μM; n = 4; Fig. 1B). As with glycine, there was no significant 
change in mean frequency of mEPSCs (0.51 ± 0.06 Hz v 0.56 ± 0.15 Hz; +11%) during perfusion with the amino acid 
when assessed with a paired t-test. However, there was a small but significant shift to the left of the cumulative 
probability distribution of events when the data were analysed as interevent interval distributions (not shown) and 
compared with a Kolmogorov–Smirnov test (P < 0.05). This change was not pronounced but was the only significant 
change detected. Mean median amplitude (6.7 ± 0.1 pA v 6.5 ± 0.3 pA), mean rise (4.3 ± 0.3 ms v 4.5 ± 0.3 ms) and 
mean decay time (5.5 ± 0.3 ms v 6.5 ± 0.3 ms) were unaltered by D-serine. 
3.2. The preNMDAR co-agonist binding site is tonically activated 
The failure of either glycine or D-serine to substantially increase the release of glutamate may suggest that the co-
agonist binding site of the preNMDAr is tonically activated at a level close to saturation in the EC. If this is the case 
then blocking the site should result in a decrease in release. To investigate this we examined the effect of DCKA, a 
co-agonist binding site antagonist. Although postNMDArs were blocked in the recorded neurones by intracellular 
MK801, these experiments (n = 4) were again conducted on mEPSCs to avoid any complicating effects of network 
activity via non-recorded neurones in which the postNMDArs were not blocked. The results are shown in Fig. 2A. 
DCKA elicited a significant decrease in mEPSC frequency to around 60% of the control level. This effect was not 
accompanied by any change in mean amplitude (8.37 ± 0.5 v 7.8 ± 0.4 pA), rise time (4.8 ± 0.3 v 4.8 ± 0.4 ms) or 
decay time (5.8 ± 0.5 v 6.0 ± 0.7 ms), and this lack of effect on mEPSCs is shown by the averaged events and the lack 
of change in amplitude distribution in Fig. 2A. Overall, these effects indicate that DCKA acts presynaptically to reduce 
the probability of glutamate release. 
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Fig. 2. A co-agonist site antagonist reduces spontaneous glutamate release. A. Application of the co-agonist binding site antagonist, DCKA (n = 
5), produced a robust decrease in mEPSC frequency, but was without effect on event amplitude. The averaged traces from one neurone show 
no change in event amplitude or kinetics, and the lack of change in amplitude is also reflected in the frequency distributions of pooled data. B. 
The competitive glutamate binding site antagonist, 2-AP5 induced a similar decrease in mEPSC frequency to that seen with DCKA, and also 
occluded the effect of the latter. In this and subsequent figures, * = P < 0.05 and ‘ns’ denotes not significant. 
To confirm that the effect of DCKA was likely to be mediated via an action at preNMDAr we examined its effect in 
the presence of the competitive NMDAr antagonist, 2-AP5 (n = 5; Fig. 2B). In accordance with our previous findings ( 
Berretta and Jones, 1996a and Woodhall et al., 2001), 2-AP5 induced a significant decrease in mEPSC frequency (0.47 
± 0.04 v 0.29 ± 0.05 Hz) without change in amplitude (8.0 ± 0.8 v 7.6 ± 0.7 pA). Subsequent perfusion with DCKA in 
the presence of 2-AP5 now failed to induce any further change in frequency. Thus, the occlusion of the effects of 
DCKA by the competitive receptor antagonist suggests that it is acting at preNMDArs and blocking the tonic 
facilitation of release enabled by binding of endogenous glutamate and a co-agonist. 
3.3. Glycine does not endogenously activate the co-agonist binding site 
Having determined that the co-agonist binding site of the preNMDAr was tonically and endogenously activated in 
our slices, we then attempted to identify the endogenous ligand responsible. The small, but significant, decrease in 
interevent interval induced by D-serine could suggest that the D-serine is the preferred ligand for the co-agonist 
binding site. To look at this further we selectively depleted the candidate ligands via enzymatic breakdown. This 
approach has been successfully used to look at endogenous ligands for the postNMDAr (Fossat et al., 2012 and 
Papouin et al., 2012). In the first set of experiments we examined the effect of degrading endogenous glycine with 
BsGO. We compared the characteristics of mEPSCs in 6 neurones in untreated brain slices to matched neurones in 
brain slices incubated with BsGO for 45 min. 
Fig. 3 illustrates the results of these experiments. The frequency of mEPSCs (0.41 ± 0.13 Hz) in slices preincubated 
with BsGO (n = 6) was not significantly different to that in matched slices without enzyme present (0.33 ± 0.04 Hz). 
Likewise, the mean amplitudes (7.7 ± 0.4 v 7.9 ± 0.9 pA), amplitude distribution ( Fig. 3), and kinetics in treated and 
untreated slices (rise time 4.4 ± 0.4 v 4.3 ± 0.4 ms; decay time 7.1 ± 0.8 v 7.2 ± 0.7 ms) were not significantly affected 
by the enzyme treatment. These data clearly suggest that endogenous glycine is unlikely to be tonically activating 
the binding site on the preNMDAr. To confirm that the site was still being activated we determined the effect of 
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DCKA in both naïve and enzyme treated slices. In both cases, the co-agonist site antagonist, as described above, 
reduced the frequency of mEPSCs ( Fig. 3) without altering either amplitude distribution ( Fig. 3) or kinetics (data not 
shown). 
 
Fig. 3. Depletion of endogenous glycine does not affect spontaneous glutamate release. Comparison of mEPSC frequencies with and without 
pre-incubation with BsGO showed no significant difference between matched control slices and slices incubated with the enzyme (n = 6 in 
each case). In the naïve slices, as noted in Fig. 2, DCKA elicited a significant reduction in mEPSC frequency, and this effect was very similar in 
the enzyme-treated slices. There were no differences in event amplitudes in any of the experimental situations and this is illustrated by the 
overlapping frequency distributions. 
3.4. D-serine endogenously activates the co-agonist site 
We next examined the effect of removal of endogenous D-serine from our slices by incubation with the yeast 
enzyme, RgDAAO, which specifically degrades D-serine (Fig. 4). The mean frequency of mEPSCs in 6 neurones in 
untreated slices was 0.65 ± 0.13 Hz. However, in 6 neurones in slices incubated with RgDAAO, mEPSC frequency was 
lowered to 0.38 ± 0.03 Hz. This substantial decline in frequency was not accompanied by differences in mean event 
amplitude (7.8 ± 0.5 pA v 7.3 ± 0.3 pA), kinetics (rise time 4.7 ± 0.3 v 5.1 ± 0.3 ms; decay time 6.0 ± 0.4 v 5.9 ± 0.7 ms) 
or amplitude distribution ( Fig. 4). As in the glycine experiments, we also studied the effects of DCKA. In naïve slices 
DCKA reduced the frequency of mEPSCs without change in amplitude or kinetics, as described above. However, pre-
treatment with RgDAAO occluded the effects of DCKA, and the co-agonist site antagonist caused no further 
reduction in frequency and no change in amplitude distribution ( Fig. 4). These results indicate that D-serine is likely 
to be the endogenous co-agonist at the preNMDAr, and that glycine, at least in the conditions pertaining to our 
slices, may play little role in this regard. 
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Fig. 4. Depletion of endogenous D-serine reduces spontaneous glutamate release. Pre-incubation of slices with the d-amino acid oxidase, 
RgDAAO to degrade endogenous D-serine resulted in a significant decrease in mEPSC frequency in comparison to matched untreated slices (n 
= 6 in each case). This reduction was similar to that seen with the co-agonist binding site antagonist, DCKA, and the effect of the latter was 
occluded by pre-incubation with the enzyme. Despite the change in frequency, event amplitudes were unaltered, exemplified by the 
overlapping frequency distributions of amplitudes from pooled data. 
3.5. Astrocytes may be the source of endogenous D-serine 
Previous studies have shown that D-serine is the likely to be the endogenous co-agonist at subsynaptic postNMDAr 
in cortex (Fossat et al., 2012 and Papouin et al., 2012) and that astroglia may be the source of the D-serine. We have 
looked at the possibility that astroglial D-serine may be the endogenous activator of preNMDArs in the EC. To this 
end we compared mEPSCs in neurones with and without preincubation with the glia-specific metabolic inhibitor, 
NFAc (Hassel et al., 1997, Hulsmann et al., 2003, Andersson et al., 2007 and Okada-Ogawa et al., 2009). The results 
are summarized in Fig. 5A. In 6 neurones recorded in naïve slices, mEPSC frequency was 0.66 ± 0.13 Hz and mean 
amplitude was 7.0 ± 0.7 pA. In matched recordings from slices pre-incubated with NFAc (n = 6), mEPSC frequency 
was much lower at 0.35 ± 0.03 Hz, but there was no change in mean amplitude (7.1 ± 0.5 pA). The amplitude 
distribution of mEPSCs was also unaltered and there were no differences in either rise or decay times in the two 
groups (not shown). We also tested the effects of the co-agonist site antagonist in the presence or absence of NFAc ( 
Fig. 5A). In the untreated slices DCKA reduced the frequency of mEPSCs, as noted above. However, when tested in 
NFAc-treated slices, DCKA had little further effect on mEPSC frequency. Comparison of the effect of DCKA in the two 
sets of slices showed a trend towards a bigger reduction in frequency when combined with NFAc, but this was not 
significant. 
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Fig. 5. Compromising astroglial function reduces spontaneous glutamate release. A. In slices pre-incubated with NFAc (n = 6), mEPSC frequency 
was substantially reduced compared to neurones in matched control slices (n = 6), and this effect was similar to that seen with DCKA and 
RgDAAO ( Fig. 2 and Fig. 4). However, the effect of DCKA was occluded by pre-incubation with NFAc. Amplitude distributions were unaffected 
by any of the experimental treatments. B. The reduction in mEPSC frequency seen with NFAc was partially rescued by application of D-serine. 
Thus, in contrast to the situation in untreated slices (Fig. 1), perfusion with D-serine increased the frequency of mEPSCs in NFAc-treated slices 
with no effect on amplitude distribution. 
Thus, compromising astroglial function induced a similar reduction in spontaneous release of glutamate to that seen 
with a co-agonist site antagonist, or enzymatic degradation of D-serine with RgDAAO, suggesting that astroglial 
release provides the D-serine required for tonic activation of the preNMDAr. However, the effect of incubation with 
NFAc was somewhat less than that of RgDAAO (cf. Fig. 4) and we cannot exclude the possible influence of neuronal 
D-serine at the preNMDAR. 
We next examined the ability of exogenous D-serine to rescue the reduction in mEPSC frequency induced by pre-
incubation with NFAc in five slices. In 5 neurones the mean frequency of mEPSCs was again lower than that seen in 
naïve slices and a significant recovery was seen upon addition of D-serine (100 μM; Fig. 5B), suggesting that it was 
indeed the loss of an endogenous D-serine supply from astroglia that resulted in a decline of tonic facilitation. 
We also determined whether a loss of endogenous D-serine would reduce the ability of direct activation of 
preNMDAr to facilitate glutamate release. To this end we compared the ability of NMDA to increase mEPSC 
frequency in the presence or absence of NFAc. In control neurones (n = 5), application of NMDA (100 μM) elicited an 
increase in frequency of mEPSCs of 131% (from 0.56 ± 0.17 Hz to 1.03 ± 0.25 Hz) with no change in amplitude (7.4 ± 
0.5 pA v 7.4 ± 0.3 pA). In 5 matched neurones treated with NFAc, the increase in frequency seen with NMDA was 
only 58% (0.32 ± 0.08 Hz v 0.49 ± 0.12 Hz), again without change in amplitude (7.5 ± 0.5 pA v 7.2 ± 0.6 pA) suggesting 
that a loss of endogenous D-serine from astroglial cells could compromise the ability of exogenous NMDA to elevate 
glutamate release. 
3.6. Effects of UBP 141, purinergic receptor blockade and mGluR antagonists 
Thus, the most parsimonious explanation of our data is that D-serine released from astrocytes is likely to be the co-
agonist at the preNMDAr on nerve terminals. However, there are a number of other possible, and more complex, 
interpretations. and we have attempted to rule some of these out with pharmacological approaches. 
Astrocytes themselves express NMDAr, and it has been suggested that these are involved in neurone-to-glia 
signalling and vice versa (Lalo et al., 2006 and Palygin et al., 2011). If these NMDAr responded to ambient glutamate, 
this could result in tonic release of astrocytic glutamate or other gliotransmitters (e.g. purines). This could 
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complicate our interpretations, since treatments aimed to modify the co-agonist site could target the astrocyte 
NMDAr rather than the glutamate terminal receptors. We have shown that the preNMDAr in the EC is likely to be 
principally, if not exclusively, a GluN1–GluN2B heteromer (Woodhall et al., 2001, Yang et al., 2006 and Chamberlain 
et al., 2008). Recent studies have suggested that NMDAr on cortical astrocytes may be largely GluN2C/D-N3-
containing heteromers (Palygin et al., 2011). We tested the effects of the relatively specific GluN2C/D antagonist, 
UBP 141 (2.5 μM; Morley et al., 2005), alone and in combination with DCKA. The mean frequency of mEPSCs in 
control conditions (n = 4) was 0.43 ± 0.09 Hz and this was unaltered by UBP 141 (0.45 ± 0.08 Hz), but subsequently 
reduced by DCKA (0.21 ± 0.02 Hz) in the continued presence of the antagonist. This argues against the reduction in 
tonic glutamate release induced by the co-agonist blocker occurring via an interaction with NMDAr on astrocytes. 
Notwithstanding the failure of UBP 141 to alter the release of glutamate or the effects of DCKA, we have considered 
other further scenarios dependent upon NMDAr activation of astrocytes by ambient glutamate. One possibility could 
involve a complex cascade mediated by purinergic transmitters. NMDAr activation can release ATP from astrocytes, 
and also lead, directly via release or indirectly via metabolism of ATP, to accumulation of extracellular adenosine 
(e.g. see Queiroz et al., 1997, Pascual et al., 2005 and Wall and Dale, 2013). Subsequent activation of purinergic 
receptors on neurones or glia could then potentially amplify tonic release of glutamate. Thus, the decrease in 
glutamate release seen with DCKA or scavenging of D-serine could result not from compromising preNMDAr but, 
rather, affecting those on the glial cells. We felt that this was unlikely on the basis of the UBP 141 experiments, but 
also because we have previously shown that both ATP and adenosine reduce, rather than enhance glutamate release 
in the EC (Saunders, J. and Jones R.S.G., unpublished). However, since the potential mechanism would depend on 
tonic activation of glutamate release by the astrocytic derived purines, we examined its viability by testing DCKA in 
the presence of broad spectrum purinergic receptor antagonists; suramin, which non-specifically targets P2 
receptors, and CGS15943, which blocks A1, A2A, A2B and A3 adenosine receptors. Neither frequency (0.50 ± 0.07 v 0.45 
± 0.04 Hz) nor amplitude (9.6 ± 1.9 v 9.3 ± 1.8 pA) of mEPSCs was altered by suramin (100 μM, n = 4). Subsequent 
perfusion with DCKA, in the continued presence of suramin, elicited a similar reduction in frequency (to 0.24 ± 0.02 
Hz) to that seen with the co-agonist site blocker alone (Section 3.2), again without change in amplitude (8.2 ± 1.4 
pA). Likewise, studies with CGS15943 (1 μM, n = 4) showed no change in frequency with the adenosine antagonist 
alone (0.30 ± 0.22 v 0.29 ± 0.07 Hz), but a significant decrease with subsequent addition of DCKA (0.19 ± 0.04 Hz). 
One further alternative mechanism could involve activation of metabotropic glutamate receptors (mGluR). 
Glutamate, released from astrocytes in response to NMDAr activation, has been shown to further tonically increase 
neuronal glutamate release via mGluRs (e.g. see Fiacco and McCarthy, 2004 and Clasadonte and Haydon, 2012). If 
such a situation was operative at EC synapses, then negatively modifying the co-agonist activation of astrocytic 
NMDAr could indirectly manifest itself as a reduced frequency of mEPSCs. We have shown previously that agonists at 
group III (Evans et al., 2000), group II (Morgan, N. et al., unpublished) and group I mGluR (Yang, J. et al., unpublished) 
agonists can all (under some circumstances) facilitate spontaneous release of glutamate in layer V of the EC, so such 
a scenario is possible. However, again for this scenario to be viable, the mGluRs in question would have to be 
tonically activated. However, we have also shown that the group III receptor antagonist, CPPG does not affect mEPSC 
frequency (Evans et al., 2000). We now report here that mEPSC frequency is unaltered (0.66 ± 0.10 v 0.71 ± 0.09 Hz) 
by the group II mGluR antagonist, LY341495 (20 nM, n = 7) or by the group I/II antagonist, MCPG (300 μM; 0.81 ± 
0.11 v 0.75 ± 1.0 Hz; n = 5). Neither the group III or the group I/II antagonist altered mEPSC amplitude (not shown) 
although there was a slight but significant increase in amplitude with LY341495 (12.3 ± 0.2 pA v 14.1 ± 0.2 pA; P < 
0.05). Overall these results suggest that mGluR activation following astroglial glutamate release is unlikely to be a 
complicating factor in the current study. 
4. Discussion 
The obligatory binding of a co-agonist amino acid to a binding site on the NMDAr for its activation was demonstrated 
25 years ago (Johnson and Ascher, 1987, Forsythe et al., 1988 and Kleckner and Dingledine, 1988). Enhancement of 
NMDAr-mediated responses by glycine initially suggested that this amino acid was the endogenous co-agonist 
(Johnson and Ascher, 1987, Berger et al., 1998, Bergeron et al., 1998, Forsythe et al., 1988 and Kleckner and 
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Dingledine, 1988) and, accordingly, the nomenclature “glycine-binding site” received common usage. However, 
increasing evidence has pointed to D-serine as an alternative endogenous co-agonist (Mothet et al., 2000, Yang et 
al., 2003, Basu et al., 2009 and Henneberger et al., 2010; Fossat et al., 2012), although a recent study (Papouin et al., 
2012) suggests that synaptic (GluN2A-containing) and extrasynaptic (GluN2B-containing) NMDAr may be 
differentially gated by D-serine and glycine, respectively (see below). All these studies relate to postNMDArs, and co-
agonist gating of preNMDArs has received much less attention. 
PreNMDArs facilitate the release of glutamate at cortical synapses (Berretta and Jones, 1996a, Woodhall et al., 2001, 
Sjostrom et al., 2003 and Li and Han, 2007Li et al., 2008). This effect is tonically expressed and dependent on 
ambient glutamate, but, of necessity, it will also require tonic activation of the obligatory co-agonist binding site. We 
have studied the basis of a co-agonist regulation of glutamate release at synapses in layer V of the EC. Neither 
glycine nor D-serine had any substantial effect on frequency, amplitude or kinetics of AMPA receptor-mediated 
sEPSCs, although cumulative probability analysis of inter-event interval did indicate a slight increase in frequency 
with D-serine but not glycine. This could support a preference for D-serine as the endogenous co-agonist, but overall 
the data suggest that co-agonist binding site is saturated, or close to it, under baseline conditions in our slices. The 
endogenous occupation of the preNMDAr co-agonist binding site was confirmed by application of a competitive 
antagonist, DCKA, which clearly decreased the frequency of EPSCs. The occlusion of this effect by prior application of 
2-AP5 indicated that DCKA was acting at the co-agonist site on the preNMDAr. Thus, at these synapses, the levels of 
ambient glutamate and its co-agonist at the preNMDAr can modulate the control and maintenance of spontaneous 
excitation. Li and Han (2007) conducted similar studies in rat visual cortex. They also found little effect of exogenous 
glycine or D-serine, but noted a decrease in probability of release with a co-agonist binding site blocker, although all 
their recordings were done in Mg-free conditions so may not be directly comparable. 
Using specific scavenging enzymes for glycine and D-serine, we have now shown that the endogenous co-agonist 
occupying the preNMDAr in the EC is almost certainly D-serine rather than glycine. Previous studies have strongly 
suggested that D-serine acts as the endogenous co-agonist at NMDArs at many postsynaptic sites (Mothet et al., 
2000, Yang et al., 2003, Basu et al., 2009 and Henneberger et al., 2010; Fossat et al., 2012), and that glycine uptake 
transporters are powerful enough to maintain extracellular glycine below its affinity for the NMDAr co-agonist site 
(Fossat et al., 2012; Papouin et al., 2012). Interestingly, Papouin et al. (2012) have recently suggested that 
postNMDArs, located subsynaptically in CA1, are preferentially gated by D-serine, whilst those at extrasynaptic sites 
preferentially bind glycine. Further, they suggest that this is related to the fact that subsynaptic receptors are 
principally GluN2A heterodimers which have a higher affinity for D-serine (Priestley et al., 1995 and Madry et al., 
2007), whereas extrasynaptically they are GluN2B-containing, which have a higher affinity for glycine (Priestley et al., 
1995, Wafford et al., 1995 and Madry et al., 2007). We have shown (Woodhall et al., 2001, Yang et al., 2006 and 
Chamberlain et al., 2008) that the preNMDAr in the EC has a diheterodimeric GluN1–GluN2B subunit composition 
(likewise in the visual cortex; Li et al., 2008). It might be expected therefore that they would preferentially bind, and 
be gated by, glycine rather than D-serine, but this was clearly not the case. Thus, the preNMDARs may represent a 
pharmacologically distinct population of NMDAr that are bound by endogenous D-serine whilst lacking GluN2A 
subunits. 
Glutamate released from astrocytes can activate neuronal NMDArs (Parri et al., 2001) and it has been shown that 
this is associated with an increase in sEPSCs, possibly via a presynaptic mechanism (Araque et al., 1998). Jourdain et 
al. (2007) confirmed that astrocytic derived glutamate could boost synaptic strength by activating neuronal 
preNMDArs. We asked what was the source of D-serine that tonically co-activates the preNMDAr? Serine racemase 
(the enzyme that reversibly converts l- to D-serine) and D-serine have been largely localized to astrocytes in the 
brain. However, there is evidence that cortical neurones may also be a source of the endogenous amino acid 
(Wolosker et al., 1999, Kartvelishvily et al., 2006, Martineau et al., 2006, Williams et al., 2006, Miya et al., 2008 and 
Rosenberg et al., 2010), so there is still debate over whether postNMDArs are activated by D-serine released from 
astrocytes or neurones (e.g. see Rosenberg et al., 2010 and Fossat et al., 2012). We found that inhibiting metabolic 
activity in astrocytes with NFAc, had the same effect on glutamate release in the EC as scavenging D-serine with 
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RgDAAO, or blocking the co-agonist binding site with DCKA. This strongly suggests that the preNMDAr is gated by 
astrocytic D-serine in the EC, rather than neuronal D-serine. However, a weak (although insignificant), reduction of 
glutamate release by DCKA in the presence of NFAc, means we cannot entirely rule out a neuronal contribution. 
Interestingly, a recent study has shown that D-serine release is increased in rat hippocampus by Isoleucine via 
exchange at the asc-1 (alanine–serine–cysteine transporter-1) and this results in enhanced NMDAr-dependent LTP 
(Rosenberg et al., 2013). We have previously shown that spontaneous glutamate release in layer V of the EC is 
unaltered by l-Isoleucine (Cunningham et al., 2004), which is essentially equieffective with d-Isoleucine as a substrate 
for asc-1 (Fukasawa et al., 2000: Helboe et al., 2003). As asc-1 is not expressed in astrocytes (Helboe et al., 2003 and 
Rosenberg et al., 2013), this could taken as support for a glial, rather than neuronal source of endogenous D-serine 
in the EC. 
However, overall, the picture emerges that activation of preNMDAr and the resultant increase in synaptic activation 
may well depend on interaction between glutamate, of neuronal origin, and D-serine, from astrocytes, at tripartite 
cortical synapses. We believe that this is the most parsimonious explanation of our results. However, since 
astrocytes themselves express NMDArs, activation of which can lead to release of glutamate and purinergic 
transmitters, other more complex scenarios are possible, which could reflect co-agonist regulation of glial, rather 
than terminal NMDAr. We have used pharmacological approaches to look at these possibilities and believe that we 
have largely ruled out a contribution of glial NMDAr-dependent activation of ATP, adenosine or mGlu receptors as 
complicating factors in our studies. Thus, whilst we cannot be 100% sure, we are, nevertheless, confident that 
preNMDAr on terminals at layer V synapses are co-activated by neuronal glutamate and astrocytic D-serine. 
What are the implications of the tonic co-agonist regulation of preNMDAr for synaptic function in the EC? One 
interesting possibility is in control of presynaptic receptor trafficking. We have previously shown (Yang et al., 2008) 
that preNMDArs can diffuse laterally within the presynaptic membrane moving between sites proximal and distal to 
the active release sites, providing a basis for an activity-dependent tonic regulation of glutamate release and hence 
synaptic strength. Recent work has suggested that GluN2B-containing postNMDAr have their lateral mobility 
restricted by D-serine (Papouin et al., 2012). We do not know yet whether the co-agonist binding of D-serine 
similarly slows diffusion of the preNMDAr, but such an effect, mediated by astroglial activity, could provide a basis 
for an activity-dependent metaplasticity of transmission at excitatory synapses in the EC. 
Interestingly, reactive astrocytosis is a feature of human temporal lobe epilepsy and animal models of the chronic 
condition (Borges et al., 2003, Borges et al., 2006, Cohen-Gadol et al., 2004, Eid et al., 2008, Shapiro et al., 2008 and 
Wetherington et al., 2008). A decrease in glutamine synthase activity in association with this has been suggested to 
elevate synaptic levels of glutamate (see Clasadonte and Haydon, 2012). Furthermore, increased levels of D-serine 
and serine racemase have been observed in pilocarpine induced epilepsy (Ryu et al., 2010). We have previously 
shown an enhanced tonic facilitation of glutamate release of preNMDAr in a similar model of chronic epilepsy (Yang 
et al., 2006), and human temporal lobe epilepsy may be associated with an increased density of preNMDAr at 
cortical synapses (Steffens et al., 2005). Thus, in temporal lobe epilepsy, we may have a situation where increased 
effectiveness of preNMDArs per se may be exacerbated by an elevation of synaptic availability of both co-agonists as 
a result of reactive gliosis, leading to a pathological rise in cortical network excitability and synchrony. 
Pharmacologically targeting the astroglial-preNMDAr synaptic amplifier may, therefore, provide a useful therapeutic 
approach to epilepsy. Use of NMDAr co-agonist binding site blockers has already received consideration (Chiamulera 
et al., 1990, Singh et al., 1990, Peterson, 1991, Peeters and Vanderheyden, 1992 and Wu et al., 2002). Interestingly, 
we have previously demonstrated that felbamate can reduce glutamate release in the EC via an action at preNMDArs 
(Yang et al., 2007), and the drug may act, at least in part, by blocking the glycine/D-serine co-agonist binding site 
(White et al., 1995, Kuo et al., 2004 and Chang and Kuo, 2007). The co-agonist binding site partial agonist, 
cycloserine, has anticonvulsant activity (Chung et al., 1984, Baran et al., 1994 and De Sarro et al., 2000; see also 
Ghasemi and Schachter, 2011), and acts as an antagonist only when a high degree of agonist occupancy of the site is 
present (Henderson et al., 1990). We have shown here that the preNMDAr co-agonist binding site in the EC is likely 
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to be endogenously saturated so this approach may be useful in achieving a degree of selectivity for blocking the 
receptor. The pro-drug, 4-chlorokynurenine, which is largely inactive but undergoes astrocytic conversion to the co-
agonist binding site blocker, 7-chlorokynuerenic acid (Zhang et al., 2005), could also be an alternative approach to 
epilepsy therapy. Finally, inhibition of serine racemase (Panizzutti et al., 2001) or enzymatic metabolism of D-serine 
(Sacchi et al., 2012) could also provide promising strategies for the development of treatments for epilepsy. 
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